Amgen gives first glimpse at PRMT5 inhibitor, days after Bristol Myers put a $1B promise on the target
In a first look at Amgen’s experimental PRMT5 inhibitor, roughly 16% of patients with various cancers saw their tumors shrink by at least 30%, equating …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
